FMR LLC and Abigail P. Johnson report beneficial ownership of 12,696,254.11 shares of 10x Genomics, Inc. Class A common stock, representing 10.8% of that class as of December 31, 2025. FMR has sole voting power over 12,658,759 shares and sole dispositive power over 12,696,254.11 shares, with no shared voting or dispositive power.
The reported amount includes 892,772 shares of Class B common stock held by investment companies advised by FMR subsidiaries, which are convertible into Class A shares on a 1:1 basis and represent 8.8579% of the outstanding Class B stock. The filing states that, assuming conversion of all outstanding Class B into Class A, the reported holding would represent 10.0324% of the Class A common stock. The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of 10x Genomics.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 13)
10x Genomics, Inc.
(Name of Issuer)
CLASS A COMMON STOCK
(Title of Class of Securities)
88025U109
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
88025U109
1
Names of Reporting Persons
FMR LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
12,658,759.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
12,696,254.11
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
12,696,254.11
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
10.8 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP No.
88025U109
1
Names of Reporting Persons
Abigail P. Johnson
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
12,696,254.11
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
12,696,254.11
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
Address or principal business office or, if none, residence:
245 Summer Street, Boston, Massachusetts 02210
(c)
Citizenship:
Not applicable
(d)
Title of class of securities:
CLASS A COMMON STOCK
(e)
CUSIP No.:
88025U109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
12,696,254.11*
*892,772 of the shares of Class A Common Stock of 10X GENOMICS INC reported as being beneficially owned by the reporting persons at December 31, 2025, are included in this Schedule 13G because the Reporting persons are deemed to beneficially own such shares as a result of the direct ownership of 892,772 shares of Class B Common Stock of 10X GENOMICS INC by investment companies advised by Fidelity Management & Research Company LLC, FIAM LLC, Strategic Advisers LLC, Fidelity Management Trust Company, indirect wholly-owned subsidiaries of FMR LLC as of such date, which shares of Class B Common Stock are convertible into shares of Class A Common Stock at the election of the holder at an exchange rate of 1:1. Such shares of Class B Common Stock represent 8.8579% of the outstanding Class B Common Stock. Assuming the conversion of all outstanding shares of Class B Common Stock into Class A Common Stock, the 12,696,254
shares of Class A Common Stock reported as being beneficially owned by the reporting persons in this Schedule 13G would represent 10.0324% of the outstanding Class A Common Stock.
(b)
Percent of class:
10.8%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Please see the responses to Items 5 and 6 on the cover page.
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
12,696,254.11*
*892,772 of the shares of Class A Common Stock of 10X GENOMICS INC reported as being beneficially owned by the reporting persons at December 31, 2025, are included in this Schedule 13G because the Reporting persons are deemed to beneficially own such shares as a result of the direct ownership of 892,772 shares of Class B Common Stock of 10X GENOMICS INC by investment companies advised by Fidelity Management & Research Company LLC, FIAM LLC, Strategic Advisers LLC, Fidelity Management Trust Company, indirect wholly-owned subsidiaries of FMR LLC as of such date, which shares of Class B Common Stock are convertible into shares of Class A Common Stock at the election of the holder at an exchange rate of 1:1. Such shares of Class B Common Stock represent 8.8579% of the outstanding Class B Common Stock. Assuming the conversion of all outstanding shares of Class B Common Stock into Class A Common Stock, the 12,696,254
shares of Class A Common Stock reported as being beneficially owned by the reporting persons in this Schedule 13G would represent 10.0324% of the outstanding Class A Common Stock.
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of 10X GENOMICS INC. No one other person's interest in the CLASS A COMMON STOCK of 10X GENOMICS INC is more than five percent of the total outstanding CLASS A COMMON STOCK.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See attached Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
FMR LLC
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:
01/07/2026
Abigail P. Johnson
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:
01/07/2026
Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003.
** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
How many 10x Genomics (TXG) shares does FMR LLC report owning?
FMR LLC reports beneficial ownership of 12,696,254.11 shares of 10x Genomics, Inc. Class A common stock as of December 31, 2025.
What percentage of 10x Genomics (TXG) Class A stock does FMR LLC own?
FMR LLC and Abigail P. Johnson report beneficial ownership of 10.8% of 10x Genomics, Inc. Class A common stock.
Who are the reporting persons in this Schedule 13G/A for 10x Genomics (TXG)?
The reporting persons are FMR LLC, a Delaware entity, and Abigail P. Johnson, a United States citizen.
How do 10x Genomics Class B shares factor into FMR LLC’s ownership?
The total includes 892,772 shares of Class B common stock, held by investment companies advised by FMR subsidiaries, which are convertible into Class A shares at a 1:1 exchange rate.
What share of 10x Genomics Class B stock does FMR’s position represent?
The 892,772 Class B shares included in the filing represent 8.8579% of the outstanding Class B common stock of 10x Genomics, Inc.
What would FMR LLC’s stake be if all 10x Genomics Class B shares converted to Class A?
Assuming conversion of all outstanding Class B into Class A, the 12,696,254 Class A shares reported would represent 10.0324% of the outstanding Class A common stock.
Is FMR LLC seeking to influence control of 10x Genomics with this stake?
The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of 10x Genomics, Inc.
